All In Biotech

Drug Trial Radar · NCT02834013

Nivolumab and Ipilimumab in Treating Patients With Rare Tumors

DART: Dual Anti-CTLA-4 and Anti-PD-1 Blockade in Rare Tumors

Last checked: Nov 19, 2026Latest source record: Jun 17, 2026 (this record)Source: ClinicalTrials.govMethods & limitations

Active, not recruiting

Status

Active, not recruiting

Enrollment

798

Actual

Start

Jan 30, 2017

Primary completion

May 1, 2026

Study completion Jun 1, 2027

Sponsor

Sponsor type
NIH
First posted
Jul 15, 2016

More drug trials from this sponsor

Design

Study type
Interventional
Phase
Phase 2
Allocation
Non randomized
Model
Parallel
Masking
None
Primary purpose
Treatment
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

This phase II trial studies nivolumab and ipilimumab in treating patients with rare tumors. Immunotherapy with monoclonal antibodies, such as nivolumab and ipilimumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. This trial enrolls participants for the following cohorts based on condition: 1. Epithelial tumors of nasal cavity, sinuses, nasopharynx: A) Squamous cell carcinoma with variants of nasal cavity, sinuses, and nasopharynx and trachea (excluding laryngeal, nasopharyngeal cancer \[NPC\], and squamous cell carcinoma of the head and neck \[SCCHN\]) B) Adenocarcinoma and variants of nasal cavity, sinuses, and nasopharynx (closed to accrual 07/27/2018) 2. Epithelial tumors of major salivary glands (closed to accrual 03/20/2018) 3. Salivary gland type tumors of head and neck, lip, esophagus, stomach, trachea and lung, breast and other location (closed to accrual) 4. Undifferentiated carcinoma of gastrointestinal (GI) tract 5. Adenocarcinoma with variants of small intestine (closed to accrual 05/10/2018) 6. Squamous cell carcinoma with variants of GI tract (stomach small intestine, colon, rectum, pancreas) (closed to accrual 10/17/2018) 7. Fibromixoma and low grade mucinous adenocarcinoma (pseudomixoma peritonei) of the appendix and ovary (closed to accrual 03/20/2018) 8. Rare pancreatic tumors including acinar cell carcinoma, mucinous cystadenocarcinoma or serous cystadenocarcinoma. Pancreatic adenocarcinoma is not eligible (closed to accrual) 9. Intrahepatic cholangiocarcinoma (closed to accrual 03/20/2018) 10. Extrahepatic cholangiocarcinoma and bile duct tumors (closed to accrual 03/20/2018) 11. Sarcomatoid carcinoma of lung 12. Bronchoalveolar carcinoma lung. This condition is now also referred to as adenocarcinoma in situ, minimally invasive adenocarcinoma, lepidic predominant adenocarcinoma, or invasive mucinous adenocarcinoma 13. Non-epithelial tumors of the ovary: A) Germ cell tumor of ovary B) Mullerian mixed tumor and adenosarcoma (closed to accrual 03/30/2018) 14. Trophoblastic tumor: A) Choriocarcinoma (closed to accrual) 15. Transitional cell carcinoma other than that of the renal, pelvis, ureter, or bladder (closed to accrual) 16. Cell tumor of the testes and extragonadal germ tumors: A) Seminoma and testicular sex cord cancer B) Non seminomatous tumor C) Teratoma with malignant transformation (closed to accrual) 17. Epithelial tumors of penis - squamous adenocarcinoma cell carcinoma with variants of penis (closed to accrual) 18. Squamous cell carcinoma variants of the genitourinary (GU) system 19. Spindle cell carcinoma of kidney, pelvis, ureter 20. Adenocarcinoma with variants of GU system (excluding prostate cancer) (closed to accrual 07/27/2018) 21. Odontogenic malignant tumors 22. Pancreatic neuroendocrine tumor (PNET) (formerly named: Endocrine carcinoma of pancreas and digestive tract.) (closed to accrual) 23. Neuroendocrine carcinoma including carcinoid of the lung (closed to accrual 12/19/2017) 24. Pheochromocytoma, malignant (closed to accrual) 25. Paraganglioma (closed to accrual 11/29/2018) 26. Carcinomas of pituitary gland, thyroid gland parathyroid gland and adrenal cortex (closed to accrual) 27. Desmoid tumors 28. Peripheral nerve sheath tumors and NF1-related tumors (closed to accrual 09/19/2018) 29. Malignant giant cell tumors 30. Chordoma (closed to accrual 11/29/2018) 31. Adrenal cortical tumors (closed to accrual 06/27/2018) 32. Tumor of unknown primary (Cancer of Unknown Primary; CuP) (closed to accrual 12/22/2017) 33. Not Otherwise Categorized (NOC) Rare Tumors \[To obtain permission to enroll in the NOC cohort, contact: S1609SC@swog.org\] (closed to accrual 03/15/2019) 34. Adenoid cystic carcinoma (closed to accrual 02/06/2018) 35. Vulvar cancer (closed to accrual) 36. MetaPLASTIC carcinoma (of the breast) (closed to accrual) 37. Gastrointestinal stromal tumor (GIST) (closed to accrual 09/26/2018) 38. Perivascular epithelioid cell tumor (PEComa) 39. Apocrine tumors/extramammary Paget's disease (closed to accrual) 40. Peritoneal mesothelioma 41. Basal cell carcinoma (temporarily closed to accrual 04/29/2020) 42. Clear cell cervical cancer 43. Esthenioneuroblastoma (closed to accrual) 44. Endometrial carcinosarcoma (malignant mixed Mullerian tumors) (closed to accrual) 45. Clear cell endometrial cancer 46. Clear cell ovarian cancer (closed to accrual) 47. Gestational trophoblastic disease (GTD) 48. Gallbladder cancer 49. Small cell carcinoma of the ovary, hypercalcemic type 50. PD-L1 amplified tumors 51. Angiosarcoma 52. High-grade neuroendocrine carcinoma (pancreatic neuroendocrine tumor \[PNET\] should be enrolled in Cohort 22; prostatic neuroendocrine carcinomas should be enrolled into Cohort 53). Small cell lung cancer is not eligible (closed to accrual) 53. Treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC)

Conditions

  • Acinar Cell Carcinoma
  • Adenoid Cystic Carcinoma
  • Adrenal Cortical Carcinoma
  • Adrenal Gland Pheochromocytoma
  • Anal Canal Neuroendocrine Carcinoma
  • Anal Canal Undifferentiated Carcinoma
  • Angiosarcoma
  • Apocrine Neoplasm
  • Appendix Mucinous Adenocarcinoma
  • Bartholin Gland Transitional Cell Carcinoma
  • Basal Cell Carcinoma
  • Bladder Adenocarcinoma
  • Breast Metaplastic Carcinoma
  • Cervical Adenocarcinoma
  • Cholangiocarcinoma
  • Chordoma
  • Colorectal Squamous Cell Carcinoma
  • Desmoid Fibromatosis
  • Endometrial Transitional Cell Carcinoma
  • Endometrioid Adenocarcinoma
  • Esophageal Neuroendocrine Carcinoma
  • Esophageal Undifferentiated Carcinoma
  • Extrahepatic Bile Duct Carcinoma
  • Extramammary Paget Disease
  • Fallopian Tube Adenocarcinoma
  • Fallopian Tube Transitional Cell Carcinoma
  • Fibromyxoid Tumor
  • Gallbladder Carcinoma
  • Gastric Neuroendocrine Carcinoma
  • Gastric Squamous Cell Carcinoma
  • Gastric Undifferentiated Carcinoma
  • Gastrointestinal Stromal Tumor
  • Gestational Trophoblastic Tumor
  • Giant Cell Carcinoma
  • Human Papillomavirus-Independent Cervical Adenocarcinoma, Clear Cell-Type
  • Intestinal Neuroendocrine Carcinoma
  • Intrahepatic Cholangiocarcinoma
  • Lung Neuroendocrine Tumor
  • Lung Sarcomatoid Carcinoma
  • Major Salivary Gland Carcinoma
  • Malignant Neoplasm of Unknown Primary
  • Malignant Odontogenic Neoplasm
  • Malignant Peripheral Nerve Sheath Tumor
  • Malignant Solid Neoplasm
  • Malignant Testicular Sex Cord-Stromal Tumor
  • Metastatic Pituitary Neuroendocrine Tumor
  • Minimally Invasive Lung Adenocarcinoma
  • Mixed Mesodermal (Mullerian) Tumor
  • Mucinous Adenocarcinoma
  • Mucinous Cystadenocarcinoma
  • Nasal Cavity Adenocarcinoma
  • Nasal Cavity Carcinoma
  • Nasopharyngeal Carcinoma
  • Nasopharyngeal Low Grade Papillary Adenocarcinoma
  • Nasopharyngeal Undifferentiated Carcinoma
  • Oral Cavity Carcinoma
  • Oropharyngeal Undifferentiated Carcinoma
  • Ovarian Adenocarcinoma
  • Ovarian Germ Cell Tumor
  • Ovarian Mucinous Adenocarcinoma
  • Ovarian Squamous Cell Carcinoma
  • Ovarian Transitional Cell Carcinoma
  • Pancreatic Acinar Cell Carcinoma
  • Pancreatic Neuroendocrine Carcinoma
  • Paraganglioma
  • Paranasal Sinus Adenocarcinoma
  • Paranasal Sinus Carcinoma
  • Parathyroid Gland Carcinoma
  • PEComa
  • Penile Squamous Cell Carcinoma
  • Peritoneal Mesothelial Neoplasm
  • Placental Choriocarcinoma
  • Primary Peritoneal High Grade Serous Adenocarcinoma
  • Pseudomyxoma Peritonei
  • Rare Disorder
  • Scrotal Squamous Cell Carcinoma
  • Seminal Vesicle Adenocarcinoma
  • Seminoma
  • Serous Cystadenocarcinoma
  • Small Intestinal Adenocarcinoma
  • Small Intestinal Squamous Cell Carcinoma
  • Spindle Cell Neoplasm
  • Teratoma With Somatic-Type Malignancy
  • Testicular Non-Seminomatous Germ Cell Tumor
  • Thyroid Gland Carcinoma
  • Tracheal Carcinoma
  • Transitional Cell Carcinoma
  • Ureter Adenocarcinoma
  • Ureter Squamous Cell Carcinoma
  • Urethral Adenocarcinoma
  • Urethral Squamous Cell Carcinoma
  • Vaginal Adenocarcinoma
  • Vaginal Squamous Cell Carcinoma, Not Otherwise Specified
  • Vulvar Carcinoma

Interventions

  • Biospecimen CollectionProcedure

    Undergo blood sample collection

  • Computed TomographyProcedure

    Undergo CT

  • Echocardiography TestProcedure

    Undergo ECHO

  • IpilimumabBiological

    Given IV

  • Magnetic Resonance ImagingProcedure

    Undergo MRI

  • NivolumabBiological

    Given IV

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Overall response rate (ORR)Time frame: Up to 10 years

Locations

1,007 sites in 2 countries. Site status is shown where the registry gives one.

  • University of Alabama at Birmingham Cancer Center

    Birmingham, Alabama

  • University of South Alabama Mitchell Cancer Institute

    Mobile, Alabama

  • Anchorage Associates in Radiation Medicine

    Anchorage, Alaska

  • Anchorage Radiation Therapy Center

    Anchorage, Alaska

  • Alaska Breast Care and Surgery LLC

    Anchorage, Alaska

  • Alaska Oncology and Hematology LLC

    Anchorage, Alaska

  • Alaska Women's Cancer Care

    Anchorage, Alaska

  • Anchorage Oncology Centre

    Anchorage, Alaska

  • Katmai Oncology Group

    Anchorage, Alaska

  • Providence Alaska Medical Center

    Anchorage, Alaska

  • Fairbanks Memorial Hospital

    Fairbanks, Alaska

  • CTCA at Western Regional Medical Center

    Goodyear, Arizona

  • Kingman Regional Medical Center

    Kingman, Arizona

  • Cancer Center at Saint Joseph's

    Phoenix, Arizona

  • Highlands Oncology Group - Fayetteville

    Fayetteville, Arkansas

  • Mercy Hospital Fort Smith

    Fort Smith, Arkansas

  • CHI Saint Vincent Cancer Center Hot Springs

    Hot Springs, Arkansas

  • NEA Baptist Memorial Hospital and Fowler Family Cancer Center - Jonesboro

    Jonesboro, Arkansas

  • University of Arkansas for Medical Sciences

    Little Rock, Arkansas

  • Highlands Oncology Group - Rogers

    Rogers, Arkansas

  • Highlands Oncology Group

    Springdale, Arkansas

  • Kaiser Permanente-Anaheim

    Anaheim, California

  • Kaiser Permanente-Deer Valley Medical Center

    Antioch, California

  • Mission Hope Medical Oncology - Arroyo Grande

    Arroyo Grande, California

  • PCR Oncology

    Arroyo Grande, California

  • Sutter Auburn Faith Hospital

    Auburn, California

  • Sutter Cancer Centers Radiation Oncology Services-Auburn

    Auburn, California

  • AIS Cancer Center at San Joaquin Community Hospital

    Bakersfield, California

  • Kaiser Permanente-Baldwin Park

    Baldwin Park, California

  • Kaiser Permanente-Bellflower

    Bellflower, California

  • Alta Bates Summit Medical Center-Herrick Campus

    Berkeley, California

  • Keck Medicine of USC Buena Park

    Buena Park, California

  • Providence Saint Joseph Medical Center/Disney Family Cancer Center

    Burbank, California

  • Mills-Peninsula Medical Center

    Burlingame, California

  • Sutter Cancer Centers Radiation Oncology Services-Cameron Park

    Cameron Park, California

  • Mercy Cancer Center - Carmichael

    Carmichael, California

  • Mercy San Juan Medical Center

    Carmichael, California

  • Eden Hospital Medical Center

    Castro Valley, California

  • UC Irvine Health Cancer Center-Newport

    Costa Mesa, California

  • Sutter Davis Hospital

    Davis, California

Showing 40 of 1,007 sites, US sites first. The full list is on the registry record.

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.